Zobrazeno 1 - 10 of 14 pro vyhledávání: '"Dols, MC"'
4
Extensive stage (ES) small-cell lung cancer (SCLC) in Spain: A review of demographic, epidemiological and clinical data from the Thoracic Tumors Registry (TTR study)
Autor: Calvo, V, Costa, EC, Guirado, M, Granados, ALO, Castro, RL, Rodriguez-Abreu, D, Campelo, RG, Morillo, ED, Juan-Vidal, O, Camps, CJ, Gonzalez-Larriba, JL, Gomez, MD, Perez, JMT, Dols, MC, Gonzalez, SC, Rodriguez, JC, Sureda, BM, Bosch-Barrera, J, Moran, T, Pulla, MP
Publikováno v: ANNALS OF ONCOLOGY
r-FISABIO. Repositorio Institucional de Producción Científica
instname
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
Annals of Oncology
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::1502afd98d250c7447d5068cfd0de7a3
https://fundanet.fisabio.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=9094
Zobrazit plný text záznamu
6
First evidence of oncologic neuropathic pain prevalence after screening 8615 cancer patients. Results of the On study
Autor: de Paredes, MLG, Gonzalez, FD, del Prado, PM, Ciriquian, JLM, Frances, SE, Dols, MC, Gonzalez, EE, Granados, ALO, Tarruella, MM, Buron, JDC, Hernandez, A, Miranda, EL, Santos, JPC, Carpeno, FJD
Publikováno v: ANNALS OF ONCOLOGY
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Background: Thirty percent to ninety percent of cancer patients suffer from pain, including neuropathic pain (NP), which results in great burden for cancer patients. Thus, it was of great interest to determine NP prevalence in cancer patients in Spai
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::3ca2812d149b86ef0a01587d28db55b3
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=12146
Zobrazit plný text záznamu
8
Akademický článek
Pembrolizumab With or Without Maintenance Olaparib for Metastatic Squamous Non-Small-Cell Lung Cancer That Responded to First-Line Pembrolizumab Plus Chemotherapy.
Autor: Hochmair M; Karl Landsteiner Institute of Lung Research and Pulmonary Oncology, Klinik Floridsdorf, Vienna, Austria., Schenker M; Sf Nectarie Oncology Center Craiova and the University of Medicine and Pharmacy of Craiova, Craiova, Romania., Dols MC; Regional and Virgen de la Victoria University Hospitals, IBIMA, Málaga, Spain; Present address: UGC Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen de la Victoria, IBIMA, Málaga, Spain., Kim TM; Seoul National University Hospital, Seoul, Republic of Korea., Ozyilkan O; Baskent University Adana Application and Research Center, Adana, Turkey., Smagina M; State Budgetary Healthcare Institution, Leningrad Regional Oncology Dispensary, Saint Petersburg, Russia., Viktoriya L; Municipal Nonprofit Enterprise Regional Oncology Center, Kharkiv, Ukraine., Kato T; Kanagawa Cancer Center, Yokohama, Japan., Fedenko A; FSBI National Center of Radiology, Moscow, Russia., De Angelis F; Integrated Health and Social Services Centres, Montérégie Centre, Greenfield Park, QC, Canada., Rittmeyer A; LKI Lungenfachklinik Immenhausen, Immenhausen, Germany., Gray JE; Moffitt Cancer Center, Tampa, FL, USA., Greystoke A; Northern Centre for Cancer Care, Newcastle upon Tyne NHS Foundation Trust, Newcastle upon Tyne, UK., Aggarwal H; Merck & Co., Inc., Rahway, NJ, USA., Huang Q; Merck & Co., Inc., Rahway, NJ, USA., Zhao B; Merck & Co., Inc., Rahway, NJ, USA., Lara-Guerra H; Merck & Co., Inc., Rahway, NJ, USA., Nadal E; Institut Català d'Oncologia (ICO), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Spain. Electronic address: esnadal@iconcologia.net.
Publikováno v: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [J Thorac Oncol] 2024 Oct 28. Date of Electronic Publication: 2024 Oct 28.
Zobrazit plný text záznamu
9
Akademický článek
Avelumab Versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients With High-Expression Programmed Death-Ligand 1-Positive Metastatic NSCLC: Primary Analysis From the Phase 3 JAVELIN Lung 100 Trial.
Autor: Reck M; LungenClinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf, Germany. Electronic address: m.reck@lungenclinic.de., Barlesi F; Université Paris Saclay, Faculté de Médecine, Kremlin Bicêtre, France; Medical Oncology department, Gustave Roussy, Villejuif, France; Present Address: Université Paris Saclay, Faculté de Médecine, Kremlin Bicêtre, France; Medical Oncology Department, Gustave Roussy, Villejuif, France., Yang JC; National Taiwan University Hospital, Taipei, Taiwan., Westeel V; Hôpital Jean Minjoz, Centre hospitalier universitaire de Besançon, UMR1098, Université de Franche, Comté, France., Felip E; Hospital Universitari Vall d'Hebron, Barcelona, Spain., Özgüroğlu M; Department of Internal Medicine, Division of Medical Oncology, Cerrahpaşa Medical Faculty, Istanbul University-Cerrahpaşa, Istanbul, Turkey., Dols MC; Medical Oncology Intercenter Unit, Regional and Virgen de la Victoria University Hospitals, IBIMA, Málaga, Spain; Present address: UGC Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen de la Victoria, IBIMA, Málaga, Spain., Sullivan R; Auckland City Hospital, Auckland, Australia., Kowalski DM; Department of Lung Cancer and Thoracic Tumours, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland., Andric Z; Clinical Center Bezanijska Kosa, Belgrade, Serbia., Lee DH; Asan Medical Center, Seoul, South Korea., Sezer A; Baskent University Adana Application and Research Center, Adana, Turkey., Hu P; EMD Serono Research & Development Institute, Inc., Billerica, Massachusetts., Wang X; EMD Serono Research & Development Institute, Inc., Billerica, Massachusetts., von Heydebreck A; the healthcare business of Merck KGaA, Darmstadt, Germany., Jacob N; the healthcare business of Merck KGaA, Darmstadt, Germany., Mehr KT; the healthcare business of Merck KGaA, Darmstadt, Germany., Park K; Division of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea; Present Address: MD Anderson Cancer Center, Houston, Texas.
Publikováno v: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [J Thorac Oncol] 2024 Feb; Vol. 19 (2), pp. 297-313. Date of Electronic Publication: 2023 Sep 24.
Zobrazit plný text záznamu
10
Akademický článek
Bintrafusp Alfa Versus Pembrolizumab in Patients With Treatment-Naive, Programmed Death-Ligand 1-High Advanced NSCLC: A Randomized, Open-Label, Phase 3 Trial.
Autor: Cho BC; Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea., Lee JS; Seoul National University Bundang Hospital, Seongnam, Republic of Korea., Wu YL; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangzhou, People's Republic of China., Cicin I; Department of Medical Oncology, Trakya University, Edirne, Turkey., Dols MC; Medical Oncology Intercenter Unit, Regional and Virgen de la Victoria University Hospitals, Instituto de Investigación Biomédica de Málaga, Málaga, Spain., Ahn MJ; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea., Cuppens K; Department of Pulmonology and Thoracic Oncology, Jessa Hospital, Hasselt, Belgium., Veillon R; Centre Hospitalier Universitaire (CHU) Bordeaux, Service des Maladies Respiratoires, Bordeaux, France., Nadal E; Catalan Institute of Oncology and Clinical Research in Solid Tumors Group, Oncobell Program, Institut d'Investigació Biomèdica de Bellvitge, L'Hospitalet, Barcelona, Spain., Dias JM; Barretos Cancer Hospital, Barretos, Brazil., Martin C; Instituto Alexander Fleming, Buenos Aires, Argentina., Reck M; Airway Research Center North, German Center for Lung Research, LungenClinic, Grosshansdorf, Germany., Garon EB; David Geffen School of Medicine, University of California, Los Angeles (UCLA), Los Angeles, California., Felip E; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain., Paz-Ares L; Department of Medical Oncology, Hospital Universitario 12 de Octubre, H12O-CNIO Lung Cancer Unit, Universidad Complutense and CiberOnc, Madrid, Spain., Mornex F; CHU Lyon, Université Claude-Bernard Lyon 1, Lyon, France., Vokes EE; University of Chicago Medicine and Biological Sciences, Chicago, Illinois., Adjei AA; Cleveland Clinic, Cleveland, Ohio., Robinson C; Washington University School of Medicine, St. Louis, Missouri., Sato M; Merck Biopharma Co., Ltd., Tokyo, Japan, an affiliate of Merck KGaA, Darmstadt, Germany., Vugmeyster Y; EMD Serono, Billerica, Massachusetts., Machl A; EMD Serono, Billerica, Massachusetts., Audhuy F; the Healthcare Business of Merck KGaA, Darmstadt, Germany., Chaudhary S; EMD Serono, Billerica, Massachusetts., Barlesi F; Aix Marseille Université, Assistance Publique Hôpitaux de Marseille, Marseille, France; Université Paris-Saclay, Gustave Roussy, Villejuif, France. Electronic address: fabrice.barlesi@gustaveroussy.fr.
Publikováno v: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [J Thorac Oncol] 2023 Dec; Vol. 18 (12), pp. 1731-1742. Date of Electronic Publication: 2023 Aug 18.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje